background image

Press Release

Press Release

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

– FDA clearance leads to first commercial IND for LSD, enabling initiation of Phase 2b dose-optimization trial of MM-120 in early 2022 –  NEW YORK, January 25, 2022 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a clinical-stage biopharmaceutical company developing psychedelic-inspired therapies for the treatment of brain-based disorders, announced […]

Read More